This filing confirms the extreme dilutive financing. The 300% warrant coverage will hang over the stock for years. Monitor for the July 7 shareholder meeting and potential Nasdaq delisting if the stock price falls below $1. Expect continued selling pressure as warrants are exercised/hedged.
Price Chart
Executive Summary
Cellectar Biosciences files securities purchase agreements for a massive $34.95M registered direct offering with 300% warrant coverage at $2.65 per share, alongside a $50K insider tranche at $2.88. The offering is extremely dilutive relative to the $14M market cap, confirming the capital raise flagged in the prior 424B5 filing.
Key Financial Metrics
Key Facts
- Gross proceeds of $34,950,000 from sale of shares and warrants at $2.65/share
- Each purchaser receives Series A, B, and C Common Warrants exercisable for 100% of the purchased shares (300% total warrant coverage) at $2.65
- Insider participation of $50,000 at $2.88/share with similar warrant structure
- Company must hold shareholder meeting by July 7, 2026 to approve warrant exercise under Nasdaq rules
- 90-day lock-up on further equity issuances and 2-year ban on variable rate transactions
- Net proceeds for working capital; company stated existing cash insufficient for regulatory strategy
Financial Impact
Gross proceeds of $34.95M, more than 2x the $14M market cap, with 300% warrant coverage creating massive potential dilution
Risk Factors
- Extreme dilution from shares and 3:1 warrant coverage
- Nasdaq minimum bid price risk
- Cash burn may require additional dilutive financing
- Potential for reverse stock split to maintain listing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-057460 |
| Document: tm2613728d1_ex10-1.htm | 0001104659-26-057460 |
| Document: tm2613728d1_ex10-3.htm | 0001104659-26-057460 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $1.19 | awaiting T+60 | — | $1.22 (+2.52%) |
Aug 13, 2026 10w ago | 8-K | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Aug 13, 2026 10w ago | Press Release | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Jun 1, 2026 21w ago | Press Release | $2.97 $2.54 | ▼ −14.48% | ▼ −15.71% | $1.22 (−58.92%) |
May 29, 2026 21w ago | S-1/A | $3.14 $2.52 | ▲ +19.75% | ▲ +20.93% | $1.22 (+61.15%) |
May 28, 2026 21w ago | DEFA14A | $3.14 $2.52 | ▼ −19.75% | ▼ −20.93% | $1.22 (−61.15%) |
May 19, 2026 22w ago | S-1 | $3.17 $2.60 | ▲ +17.98% | ▲ +22.98% | $1.22 (+61.51%) |
May 14, 2026 23w ago | 8-K | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 14, 2026 23w ago | Press Release | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 11, 2026 24w ago | Press Release | $3.06 $2.52 | ▼ −17.65% | ▼ −22.04% | $1.22 (−60.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers